摘要
目的评价多西他赛联合雄激素剥夺疗法(ADT)治疗转移性去势敏感性前列腺癌(mHSPC)患者的疗效,并分析其预后影响因素。方法回顾性分析107例mHSPC患者的临床资料,所有患者均行多西他赛联合ADT治疗,观察终点为前列腺特异性抗原无进展生存期(PSAPFS)和影像学无进展生存期(rPFS)。采用Cox单因素和多因素回归分析患者PSAPFS和rPFS的相关预后影响因素。结果中位随访时间36月,13例患者死亡。中位PSAPFS34.000(30.878~37.122)月,中位rPFS33.000(30.031~35.969)月。单因素回归分析显示:初始血清PSA值、治疗7月时PSA最低值是否低于0.2ng/dl、化疗周期数、患者体能状态评分(ECOG)、是否伴有内脏转移与患者的PSAFPS、rPFS显著相关。多因素回归分析显示:治疗7月时PSA最低值是否低于0.2ng/dl以及是否伴有内脏转移与患者的PSAFPS、rPFS显著相关。结论多西他赛联合ADT治疗中国mHSPC患者疗效较好,治疗7月时PSA最低值是否低于0.2ng/dl以及是否伴有内脏转移是患者PSAFPS、rPFS的独立预后因素。
Objective To assess the efficacy of docetaxel plus ADT on mHSPC patients and analyze the prognostic factors. Methods We retrospectively reviewed the clinical data of 107 mHSPC patients treated with docetaxel plus ADT. Co-primary end points were PSA PFS and rPFS. Univariable and multivariable Cox analyses were performed to determine prognostic factors for PSA PFS and rPFS. Results The median follow-up time was 36 months, and 13(12.1%) patients died. The median PSA PFS and rPFS were 34.000(30.878-37.122) and 33.000(30.031-35.969) months, respectively. Univariate analysis results showed that the serum PSA, PSA nadir at 7 th month(≤0.2 ng/dl vs.>0.2 ng/dl), number of chemotherapy cycles(≤6 vs.7-12), ECOG PS(0-1 vs. 2) and visceral disease(yes vs. no) were independent predictors for PSA PFS and rPFS. Multivariate analysis results showed that PSA nadir at 7 th month(≤0.2 ng/dl vs.>0.2 ng/dl) and visceral disease(yes vs. no) were independent predictors for PSA PFS and rPFS. Conclusion The effect of docetaxel plus ADT on patients with mHSPC in China is favorable. PSA nadir at 7 th month(≤0.2 ng/dl vs.>0.2 ng/dl)and visceral disease(yes vs. no) are independent predictors for PSA PFS and rPFS.
作者
刘三河
崔殿生
贾全安
段丽群
邓康俐
黄雷
魏少忠
LIU Sanhe;CUI Diansheng;JIA Quan’an;Duan Liqun;DENG Kangli;HUANG Lei;WEI Shaozhong(Department of Urology, Hubei Cancer Hospital, Wuhan 430079, China)
出处
《肿瘤防治研究》
CAS
CSCD
2019年第6期526-531,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(81700669)
湖北省自然科学基金(2016CFB217)
